Skip to main content

Table 10 Selected phase I clinical trials conducted with Navitoclax as a single or combined therapeutic in untreated and pre-treated patients with Docetaxel (DOC), Erlotinib (ERLO), Gemcitabine (GEM), Carboplatin (CARB), Paclitaxel (PAC), Etopiside (ETOP), Cisplatin (CISP) against Advanced Solid Tumors (AST), non-small cell lung cancer (NSCLC), Prostate Cancer (PC), Squamous cell carcinoma (SCC) and lymphoid malignancies (LM) for Maximum Tolerated Doses (MTD) outcomes

From: BH3-mimetics: recent developments in cancer therapy

Navitoclax Combined Patients Disease Outcomes ORR Stabilized Ref
NCT00888108 DOC 39/41 Pre-Treated AST MTD 4/35 PR [392]
NCT01009073 ERLO NSCLC, PC, SCC MTD 0% ORR 27% [393]
NCT00887757 GEM Pre-Treated ST MTD 0% ORR 54% [394]
NCT00891605 CARB/PAC ST TERMINATED 5.3% PR 36.80% [395]
NCT00878449 ETOP/CISP Untreated (14 days) SCLC MTD [396]
NCT00445198 -single- Pre-Treated NSCLC, ST 0% 1/47 PR 22.8% (13 m) [390]
NCT00406809 -single- LM MTD 10/46 PR [389, 397]
  1. The clinical trials reference numbers highlighted in bold (left column), the evaluation of a single therapy alone is highlighted by -single-. Objective Response Rates (ORR) and Partial Responses (PR) are expressed as responding patient numbers/numbers assessed, or as percentages (%). Disease stabilization (Stabilized) effects (as percentage responders) are highlighted in months (m). The corresponding references for the studies are highlighted in the column on the right (Ref)